Urinary Proteomics for Endometrial Cancer Biomarker Discovery

A case-control study of 40 women (20 endometrial cancer patients and 20 controls) recruited from King Khalid University Hospital. Untargeted label-free LC-MS/MS mass spectrometry identified 193 differentially expressed proteins (117 upregulated, 76 downregulated) in urine samples. The dataset was created by Khalid Akkour and last updated on April 9, 2026.

Use Cases

• Identify candidate protein biomarkers for endometrial cancer based on differential expression analysis.
• Validate the diagnostic potential of specific proteins (e.g., GLUD1, Iduronate 2-sulfatase, histidine-rich glycoprotein) using receiver operating curve analysis.
• Investigate molecular pathways associated with endometrial cancer, such as Fc gamma receptor-dependent phagocytosis and complement activation.
• Perform multivariate statistical analysis (PCA, PLS-DA, OPLS-DA) to separate cancer and control groups based on proteomic profiles.

Strengths

• Includes data from 40 participants with matched age groups.
• Identifies 193 significantly dysregulated proteins with specific counts of upregulated (117) and downregulated (76) proteins.
• Provides AUC values (0.945, 0.965, 0.875) for three key biomarkers in ROC analysis.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The dataset is small (181.8 KB), suggesting limited scope.
• Data may reflect geographic bias inherent to recruitment from a single hospital in Saudi Arabia.

Provenance

Source

figshare

Collection Method

Untargeted label-free LC-MS/MS mass spectrometry combined with bioinformatics analysis.

Freshness

Last updated 2026-04-09 05:15:40

Geography

Participants recruited from King Khalid University Hospital, King Saud University, Saudi Arabia.